Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442834 | 1.00 | GRM4 (0.34) | GRM4ROCK2NR1I2DGAT1GRM1 | |
| SCHEMBL2434764 | 0.95 | GRM4 (0.35) | GRM4ROCK2NR1I2DGAT1GRM1 | |
| SCHEMBL2434765 | 0.95 | GRM4 (0.35) | GRM4ROCK2NR1I2DGAT1GRM1 | |
| SCHEMBL9933479 | 0.91 | GRM4 (0.33) | GRM4ROCK2NR1I2PARP1 | |
| SCHEMBL17244339 | 0.91 | GRM4 (0.33) | GRM4ROCK2NR1I2 | |
| SCHEMBL2430602 | 0.90 | GRM4 (0.33) | GRM4ROCK2NR1I2DGAT1GRM1 | |
| SCHEMBL2430605 | 0.90 | GRM4 (0.33) | GRM4ROCK2NR1I2DGAT1GRM1 | |
| SCHEMBL2435943 | 0.88 | GRM4 (0.38) | GRM4ROCK2PARP1 | |
| SCHEMBL2435948 | 0.88 | GRM4 (0.38) | GRM4ROCK2PARP1 | |
| SCHEMBL2428710 | 0.86 | GRM4 (0.37) | GRM4ROCK2DGAT1GRM1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507249-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8765722-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8501714-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2507249-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011031669-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | GRM4 4343/4885ROCK2 4729/4885NR1I2 88/4885 |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | GRM4 4343/4885ROCK2 4729/4885NR1I2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.